Dana­her out­does low fourth-quar­ter rev­enue ex­pec­ta­tions, fore­casts slow 2024

Dana­her’s rev­enue for the last three months of 2023 dropped by 11.5% com­pared to the same time in 2022, yet this was a bet­ter out­come than ex­pect­ed, with rev­enue pri­mar­i­ly gen­er­at­ed from its mol­e­c­u­lar di­ag­nos­tics sub­sidiary Cepheid, the com­pa­ny said Tues­day morn­ing.

The con­glom­er­ate al­so not­ed that its core 2024 rev­enue is pre­dict­ed to de­cline to “high-sin­gle dig­its” for the first quar­ter of 2024 and “low-sin­gle dig­its” for the whole year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER